Q290-295: POEMS Syndrome Assessment at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion

!Complete questions 290-295 for POEMS patients only. If POEMS was not reported as the primary disease for transplant (question 1) or as a preceding / concurrent disorder (question 2), submit the form.

Questions 290 – 292: Vascular endothelial growth factor (VEGF) serum value

Vascular endothelial growth factor (VEGF) promotes the growth of new blood vessels and acts as a signaling protein influencing the rate at which this process is performed. Indicate whether the serum-derived vascular endothelial growth factor (VEGF) value was Known or Unknown at the last evaluation prior to the start of the preparative regimen. If Known, report the value (in pg/mL) and specify the upper limit of normal. If Unknown, continue with question 293.

Questions 293 – 295: Vascular endothelial growth factor (VEGF) plasma value

Vascular endothelial growth factor (VEGF) promotes the growth of new blood vessels and acts as a signaling protein influencing the rate at which this process is performed. Indicate whether the plasma-derived vascular endothelial growth factor (VEGF) value was Known or Unknown at the last evaluation prior to the start of the preparative regimen. If Known, report the value (in pg/mL) and specify the upper limit of normal. If Unknown, continue with First Name.

Section Updates:

Question Number	Date of Change	Add/Remove/Modify	Description	Reasoning (If applicable)
.	.	.	.	.

Copyright © 2004-2024 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.